Market news

Astrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.

The companies will start by testing ivonescimab with an AstraZeneca ADC in gastrointestinal cancers

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration. UBS said the investment gives AstraZeneca exposure to the programmed...

Summit Therapeutics (SMMT) shares rose early Tuesday after British drugmaker AstraZeneca (AZN) agree

AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-Ve.

AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.

Summit Therapeutics (NASDAQ:SMMT) shares rose 22% in pre-market trading on Tuesday after AstraZeneca (NASDAQ:AZN) agreed to make a $2 billion strategic equity investment in the biotechnology company. The investment will be made through newly issued convertible preferred shares at an effective common stock equivalent price of $18.

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

AstraZeneca shares hit a July high after investing in Summit to co-develop cancer drug ivonescimab.

Rolling coverage of the latest economic and financial news

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc. as part of a wider cancer drug collaboration. The investment will give AstraZeneca rights equivalent to about 12% of Summit’s outstanding common stock, or about 10.6%...

Sept 29 () - HUTCHMED (China) said on Tuesday that Anglo-Swedish drugmaker ‌AstraZeneca had applied to ‌the US Food and Drug Administration for ​approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer. ORPATHYS is being jointly developed ‌by AstraZeneca ⁠and HUTCHMED and is commercialised by AstraZeneca.

AstraZeneca will put about $2 billion into Summit after the latter flagged in July that its cash pile was not enough to fund planned operations for a full year.

It was reported on September 25 that the U.S. FDA has accepted and granted Priority Review to AstraZeneca PLC (NYSE:AZN)’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) in combination with enfortumab vedotin (EV). The regimen treats muscle-invasive bladder cancer (MIBC) in patients ineligible for or declining cisplatin-based chemotherapy. Supported by Phase III VOLGA trial […]

Investing.com -- Summit Therapeutics PLC (NASDAQ:SMMT) shares surged 15% in extended trading on Monday after pharmaceutical giant AstraZeneca PLC (NYSE:AZN) agreed to make a $2.0 billion strategic equity investment in the biopharmaceutical company. The substantial capital infusion underpins a multi-pronged collaboration designed to pair Summit’s flagship bispecific antibody, ivonescimab, with AstraZeneca’s extensive oncology pipeline.

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. While the regimen demonstrated numerical improvement over standard anastrozole plus palbociclib, it did not […]

AstraZeneca (AZN) wins EU label expansion for asthma therapy Trixeo Aerosphere as a late-line maintenance option for patients aged 12 years and older. Read more here.

AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.

AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo’s Enhertu has been cleared for use by England’s National Health Service (NHS) for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE’s revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices. Around […]

In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in...

On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient population, reinforcing the company’s forecast that the drug could generate more […]

On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer. Even though an FDA advisory panel voted in April that the drug lacked patient benefit. The approval covers use alongside a CDK4/6 inhibitor for patients with […]